tetano
Editor, Senior Moderator
Oxf Med Case Reports
. 2020 Jun 25;2020(6)
maa042.
doi: 10.1093/omcr/omaa042. eCollection 2020 Jun.
Hydroxychloroquine-induced Stevens-Johnson Syndrome in COVID-19: A Rare Case Report
Lotfollah Davoodi[SUP] 1 [/SUP], Hamed Jafarpour[SUP] 2 [/SUP], Armaghan Kazeminejad[SUP] 3 [/SUP], Eissa Soleymani[SUP] 4 [/SUP], Zahra Akbari[SUP] 1 [/SUP], Alireza Razavi[SUP] 2 [/SUP]
AffiliationsExpand
Abstract
The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 that has affected >0.8 million individuals. Self-limiting respiratory tract involvement, severe pneumonia, multiorgan failure and death are the spectrum of COVID-19. To date, there are no especial therapeutic agents for COVID-19 infections. One such medication includes the antimalarial hydroxychloroquine (HCQ), which recently reported as a possible therapy for shortening the duration of COVID-19 symptoms, reducing inflammatory reactions to infection, impairing the exacerbation of pneumonia and boosting lung imaging findings. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Here, we report on the case of a 42-year-old woman, presented with fever and dry cough, who had COVID-19 and 2 days later presented with a pruritic erythematous maculopapular rash, which started from the distal of upper extremities and rapidly, involved the entire body.
. 2020 Jun 25;2020(6)
maa042.doi: 10.1093/omcr/omaa042. eCollection 2020 Jun.
Hydroxychloroquine-induced Stevens-Johnson Syndrome in COVID-19: A Rare Case Report
Lotfollah Davoodi[SUP] 1 [/SUP], Hamed Jafarpour[SUP] 2 [/SUP], Armaghan Kazeminejad[SUP] 3 [/SUP], Eissa Soleymani[SUP] 4 [/SUP], Zahra Akbari[SUP] 1 [/SUP], Alireza Razavi[SUP] 2 [/SUP]
AffiliationsExpand
- PMID: 32617169
- PMCID: PMC7315925
- DOI: 10.1093/omcr/omaa042
Abstract
The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 that has affected >0.8 million individuals. Self-limiting respiratory tract involvement, severe pneumonia, multiorgan failure and death are the spectrum of COVID-19. To date, there are no especial therapeutic agents for COVID-19 infections. One such medication includes the antimalarial hydroxychloroquine (HCQ), which recently reported as a possible therapy for shortening the duration of COVID-19 symptoms, reducing inflammatory reactions to infection, impairing the exacerbation of pneumonia and boosting lung imaging findings. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Here, we report on the case of a 42-year-old woman, presented with fever and dry cough, who had COVID-19 and 2 days later presented with a pruritic erythematous maculopapular rash, which started from the distal of upper extremities and rapidly, involved the entire body.